Criminal
Oct. 15, 2011
Amgen goes to the US Supreme Court to redefine kickbacks
Why this biotech company has nothing to lose. By Matthew Zandi of Steel Zandi
The world's largest biotech company, Amgen, has asked the U.S. Supreme Court to review a 1st U.S. Circuit Court of Appeals decision finding that Amgen could be held liable for claims involving kickbacks - money, discounts, and incentives that Amgen paid to doctors. At issue in the Amgen case is whether a violation of the Anti-Kickback Statute can form the basis for liability under the False Claims Act (FCA).
In June of 2011,...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In